An interventional study of StenoFood App in Diabetes Type 2 and Kidney Disease, sponsored by Steno Diabetes Center Copenhagen. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Steno Diabetes Center Copenhagen · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen — 8 open to participants now, 10 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Steno Diabetes Center Copenhagen.
Among the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, this one is the 7th largest by planned enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2026, is one of 17 with no phase, and was the 28th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →8 of the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen are open now, in 2 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18+
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 65+
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18+
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 50–75 · Healthy volunteers
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 94 across the 24 interventional studies, 148 across the 6 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Steno Diabetes Center Copenhagen is the lead sponsor of 114 studies on the registry; 22 are open to participants now.
3 of the studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07262788Steno Diabetes Center CopenhagenA Feasibility Study of Optimal Non-Pharmacological Lifestyle Modifications in People With Type 2 Diabetes | 2027-03 |
| NCT07645079Steno Diabetes Center CopenhagenAutomated Insulin Delivery Versus Daily Injections for Hospital Diabetes Care | 2027-07-15 |
| NCT07641309Steno Diabetes Center CopenhagenMeasurements Before and After Participation in a Health Intervention Programme in Halsnaes Municipality | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates whether a digital patient education program can improve adherence to KDIGO 2022 dietary recommendations (low sodium and optimal protein intake) among patients with type 2 diabetes and chronic kidney disease (eGFR 30-59 ml/min).
The study investigates the effect of a newly developed digital education platform, the StenoFOOD app, which provides personalized dietary guidance for individuals with type 2 diabetes and reduced kidney function. Participants are followed for six months, during which changes in sodium and protein intake are assessed, together with blood pressure and several exploratory outcomes.
Participants are assigned to one of two groups. The intervention group is recruited from Steno Diabetes Center Copenhagen and receives the app-based educational program, which includes dietary guidance and self-monitoring tools. The control group is recruited from Nordsjællands Hospital and receives standard care in the diabetes outpatient clinic. The primary outcome is the change in sodium intake, estimated from 24-hour urinary sodium excretion. Secondary outcomes include changes in protein intake, while exploratory outcomes cover blood pressure, albuminuria, potassium and phosphate excretion, food literacy, digital health literacy, and patient-reported measures.
Eligibility requires a diagnosis of type 2 diabetes, age between 18 and 74 years, a BMI below 35, and moderately reduced kidney function. Participants must also have stable medical treatment for at least three months and be able to read and understand Danish. Exclusion criteria include other types of diabetes, active cancer, certain gastrointestinal conditions, a vegan diet, or the use of sodium chloride tablets. Access to the digital platform is required for those assigned to the intervention arm.
The study is conducted at Steno Diabetes Center Copenhagen in Herlev and at Nordsjællands Hospital in Hillerød. It is sponsored by Steno Diabetes Center Copenhagen with collaboration from Rigshospitalet and Nordsjællands Hospital. The study has been approved by the Regional Ethics Committee in the Capital Region of Denmark.A total of 104 participants are expected to be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard care at diabetes outpatient clinic
Device: StenoFood App
Digital patient education program (app-based) with dietary guidance and self-monitoring tools
Also known as: SBI-Steno_Food_Concept
Change in sodium excretion between measurements at baseline and 6 months follow-up
Sodium intake (g/day) will be estimated by the average of 2 collections of 24-hour urinary sodium at both baseline and follow-up
Time frame: 6 month
Change in protein intake (g/kg/day) between baseline and follow-up measurements
Protein intake will be estimated from the average of 2 collections of 24 hour urinary urea nitrogen at both baseline and follow-up
Time frame: 6 months
Change in Blood pressure between baseline and follow-up
average of the two last blood preassure measurements out of three
Time frame: 6 months
Change in albumin, potassium and phosphate excretion between baseline and follow-up
biochemical analysis of albumin, potassium, phosphate excreted in 2\* 24 hour urine collections at baseline and follow-up
Time frame: 6 month
Change in dietary patterns between baseline and follow-up
at both baseline and follow-up participants will fill in a three day food record as well as screeners for salt and protein intake
Time frame: 6 months
Changes between baseline and follow-up in blood lipids
At both baseline and follow-up participants and controls will have blood samples taken for biochemical analyses of blood lipids
Time frame: 6 months
Change in selfreported health, motivation, self efficcacy, food and healthy literacy baseline and follow-up
at both baseline and follow-up participants will answer questionnaires on food literacy, health literacy, selfperceived health, motivation, selfefficacy and health literacy
Time frame: 6 months
Salt intake measured by spot-urine dipstick measurements
Feasibility study of dipstick measurements for self-monitoring of saltintake based on two morning and one evening measurements by the Quantab chloride dipsticks
Time frame: every month participants are invited to take three spoturine sample over 24 hrs and measure them with the Quantab chloride dipsticks
Plan to share: No
Start is estimated for Mar 2026; primary completion for Dec 2027, 21 months later.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 21 months is close to that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Steno Diabetes Center Copenhagen →